Pune 15 March 2024:Indore is set to witness a monumental milestone in the pharmaceutical industry with the cutting-edge manufacturing facility to be established by SAVA Healthcare Limited, a leading name in the pharmaceutical industry and a trusted name in the respiratory segment. The company will conduct a ground-breaking ceremony in the Smart Industrial Park (SIP) of Madhya Pradesh Industry Development Corporation (MPIDC)on March 16.
This green field project will expand the manufacturing capabilities of SAVA Healthcare Limited as well as contribute to the development of the local economy bycreating 1000+ job opportunities and offering advance skill development for the locals.
Speaking about the new manufacturing plant, Vinod Jadhav, Chairman, SAVA Healthcare Limited, said: “We are thrilled to commence this facility as it marks the initiation of a transformative phase in our journey. We want to emerge as a key player in the global contract manufacturing landscape and by expanding our manufacturing capabilities, we not only achieve that but also elevate Indore’s position in the pharmaceutical landscape.”
Nestled strategically on 13.8 acres of prime land, the forthcoming facility will boast of modern infrastructure and technologies designed to meet the stringent regulatory standards such as EuGMP / USFDA of global pharmaceutical markets, especially Europe and the United States of America.
The construction of the facility is slated to be executed in two planned phases. The first phase with a built-up area of 29,000 square meter is targeted for completion within 12 months, while the second phase will be completed by 2026.
“The new manufacturing facility will cater to the growing demand of quality pharmaceuticals in India and globally. Through this expansion, we will additionally create meaningful opportunities for the people in the region,”said Dinesh Kapoor, Managing Director, SAVA Healthcare Limited.
The new manufacturing plant in Indore will boost the manufacturing capability of SAVA Healthcare, which already operates aHealth Canada, PIC/s approved facility in Gujarat’s Surendranagar. The proposed plant will have a projected annual production capacity of 2,351.3 million stock keeping units which will include tablets, capsules, dry powder for oral suspension, ointments, nasal sprays and dry powders for inhalation.
In the past decade, SAVA Healthcare’s business vertical catering to animal healthcare, SAVAVET, has emerged as a leader in the small animal pharmaceutical business, and growing CMO/ CDMO business with leading Pharma companies in the Indian and overseas market.
SAVA Healthcare is a trusted manufacturing partner to top Indian pharmaceutical companies and has a global footprint with exports of pharmaceutical products to more than 35 countries including Canada, Ukraine, the CIS, Asia and Africa (especially FWA – French West Africa).
